ADC-Pertuzumab Promising as New Standard in HER2-Positive Metastatic Breast Cancer

By News Health
4 weeks Ago

(MedPage Today) — CHICAGO — First-line trastuzumab deruxtecan (T-DXd) combined with pertuzumab (Perjeta) improved progression-free survival (PFS) in HER2-positive locally advanced or metastatic breast cancer, according to the DESTINY-Breast09…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115844

Author :

Publish date : 2025-06-02 12:00:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Low-Dose Aspirin Reduces Colon Cancer Risk in Patients With Lynch Syndrome

Flu Shot in Pregnancy Tied to Fewer Infections in Young Infants

Supreme Court Ruling Preserves Access to Preventive Services

Disparities in Access to Opioid Use Disorder Medications Persist

Polymer Valve's Strong Debut in Mitral Valve Surgery

JAK Inhibitors' Cancer Risk Confirmed in Real-World Data